Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:APS8, a polymeric alkylpyridinium salt blocks [alpha]7 nAChR and induces apoptosis in non-small cell lung carcinoma
Authors:ID Zovko, Ana (Author)
ID Viktorsson, Kristina (Author)
ID Lewensohn, Rolf (Author)
ID Kološa, Katja (Author)
ID Filipič, Metka (Author)
ID Xing, Hong (Author)
ID Kem, William R. (Author)
ID Paleari, Laura (Author)
ID Turk, Tom (Author)
Files:URL URL - Source URL, visit http://www.mdpi.com/1660-3397/11/7/2574
 
.pdf PDF - Presentation file, download (973,49 KB)
MD5: 1933F4A3AE898A003AAF96BFBE7EF34B
 
URL URL - Source URL, visit https://doi.org/10.3390/md11072574
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo NIB - National Institute of Biology
Abstract:Naturally occurring 3-alkylpyridinium polymers (poly-APS) from the marine sponge Reniera sarai, consisting of monomers containing polar pyridinium and nonpolar alkyl chain moieties, have been demonstrated to exert a wide range of biological activities, including a selective cytotoxicity against non-small cell lung cancer (NSCLC) cells. APS8, an analog of poly-APS with defined alkyl chain length and molecular size, non-competitively inhibits α7 nicotinic acetylcholine receptors (nAChRs) at nanomolar concentrations that are too low to be acetylcholinesterase (AChE) inhibitory or generally cytotoxic. In the present study we show that APS8 inhibits NSCLC tumor cell growth and activates apoptotic pathways. APS8 was not toxic for normal lung fibroblasts. Furthermore, in NSCLC cells, APS8 reduced the adverse anti-apoptotic, proliferative effects of nicotine. Our results suggest that APS8 or similar compounds might be considered as lead compounds to develop antitumor therapeutic agents for at least certain types of lung cancer.
Keywords:3-alkylpyridinium polymers, apoptosis, nicotine, nicotinic acetylcholine receptor, non-small cell lung carcinoma
Publication status:Published
Publication version:Version of Record
Publication date:16.07.2013
Year of publishing:2013
Number of pages:str. 2574-2594
Numbering:Vol. 11, no. 7
PID:20.500.12556/DiRROS-20018 New window
UDC:577.1
ISSN on article:1660-3397
DOI:10.3390/md11072574 New window
COBISS.SI-ID:2854223 New window
Note:Nasl. z nasl. zaslona; Opis vira z dne 20. 8. 2013;
Publication date in DiRROS:02.08.2024
Views:7
Downloads:4
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Marine drugs
Shortened title:Mar. drugs
Publisher:MDPI
ISSN:1660-3397
COBISS.SI-ID:23578841 New window

Document is financed by a project

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J1-4044-2011
Name:Apoptotično delovanje alkilpiridinijevih spojin na celice pljučnega adenokarcinoma

Funder:EC - European Commission
Project number:266033
Name:Sponge Enzymes and Cells for Innovative AppLications
Acronym:SPECIAL

Funder:Other - Other funder or multiple funders
Project number:120761
Name:Swedish Cancer Society

Funder:Other - Other funder or multiple funders
Project number:10 1493
Name:Stockholm Cancer Society

Funder:Other - Other funder or multiple funders
Project number:11 1213
Name:Stockholm Cancer Society

Funder:Other - Other funder or multiple funders
Project number:90266701/2009

Licences

License:CC BY 3.0, Creative Commons Attribution 3.0 Unported
Link:https://creativecommons.org/licenses/by/3.0/deed.en
Description:You are free to reproduce and redistribute the material in any medium or format. You are free to remix, transform, and build upon the material for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Back